PRGN-2009
AXP000160.1 · Cancer vaccine
- Platform
- gorilla adenovirus (AdenoVerse, non-replicating)
- Originator
- Precigen
- Sponsor
- Precigen
Names
| Name | Type | Source |
|---|---|---|
| PRGN-2009 | preferred name, code | curator, ncit |
| Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- gorilla adenovirus
- Replication
- non replicating
- Modifications
- non-replicating gorilla adenovirus vector (AdenoVerse platform)
- Transgenes
- HPV-16 and HPV-18 E6 and E7
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C172914
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Recruiting | Phase 2 | 2025-11-11 | 2026-11-11 | 24 | Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Metastatic Cervical Cancer; Recurrent Cervical Carcinoma |
| NCT06223568 | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer | Recruiting | Phase 2 | 2024-06-10 | 2028-01-10 | 70 | Cancer Vaccine; Drug Therapy; Human Papillomavirus Viruses; Oropharynx; Squamous Cell Carcinoma of the Head and Neck |
| NCT05996523 | Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer | Active not recruiting | Phase 2 | 2023-11-07 | 2025-05-22 | 26 | Oropharyngeal Squamous Cell Carcinoma (SCC) |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | Completed | Phase 1/2 | 2020-08-11 | 2022-11-22 | 39 | Anal Cancer; Cervical Cancer; HPV Positive Cancer; Oropharyngeal Cancer; Vulvar, Vaginal, Penile, Rectal Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40116923 | PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer. | Cancer immunology, immunotherapy : CII | 2025 | cited by trial NCT04432597 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33651712 | Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009. | JCI insight | 2021 | name in title: PRGN-2009 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: PRGN-2009 |
| ZIDDC000075 | NIDCD Core for Clinical Research and Care | NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS | LEVY, JOSHUA | 2021–2025 | name in abstract: PRGN-2009 |
| ZIABC010944 | Strategies for Cancer Immunotherapy Development: Preclinical Studies | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2011–2024 | name in abstract: PRGN-2009 |
Notes
Gorilla adenovirus expressing HPV-16 and HPV-18 E6/E7 antigens with multiple cytotoxic T-cell epitopes; phase 1/2 in HPV-associated cancers, including with bintrafusp alfa and in recurrent oropharyngeal cancer. Separate construct from PRGN-2012 (AXP000159), which carries HPV 6/11.
How to cite
PRGN-2009 (AXP000160.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000160.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.